Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID‐19
- 1 May 2020
- journal article
- research article
- Published by Wiley in Drug Development Research
- Vol. 81 (7) , 768-770
Abstract
In late 2019, a new coronavirus emerged in Wuhan Province, China, causing lung complications similar to those produced by the SARS coronavirus in the 2002–2003 epidemic. This new disease was named COVID‐19 and the causative virus SARS‐CoV‐2. The SARS‐CoV‐2 virus enters the airway and binds, by means of the S protein on its surface to the membrane protein ACE2 in type 2 alveolar cells. The S protein‐ACE2 complex is internalized by endocytosis leading to a partial decrease or total loss of the enzymatic function ACE2 in the alveolar cells and in turn increasing the tissue concentration of pro‐inflammatory angiotensin II by decreasing its degradation and reducing the concentration of its physiological antagonist angiotensin 1–7. High levels of angiotensin II on the lung interstitium can promote apoptosis initiating an inflammatory process with release of proinflammatory cytokines, establishing a self‐powered cascade, leading eventually to ARDS. Recently, Gurwitz proposed the tentative use of agents such as losartan and telmisartan as alternative options for treating COVID‐19 patients prior to development of ARDS. In this commentary article, the authors make the case for the election of telmisartan as such alternative on the basis of its pharmacokinetic and pharmacodynamic properties and present an open‐label randomized phase II clinical trial for the evaluation of telmisartan in COVID‐19 patients (NCT04355936).Keywords
This publication has 20 references indexed in Scilit:
- Counter-regulatory renin–angiotensin system in cardiovascular diseaseNature Reviews Cardiology, 2019
- Angiotensin II-induced podocyte apoptosis is mediated by endoplasmic reticulum stress/PKC-δ/p38 MAPK pathway activation and trough increased Na+/H+ exchanger isoform 1 activityBMC Nephrology, 2018
- A Systematic Comparison of the Properties of Clinically Used Angiotensin II Type 1 Receptor AntagonistsPharmacological Reviews, 2013
- Angiotensin-converting enzyme 2 is a key modulator of the renin–angiotensin system in cardiovascular and renal diseaseCurrent Opinion in Nephrology and Hypertension, 2011
- The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: A retrospective analysis of 50 studiesBlood Pressure, 2008
- Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor γCardiovascular Research, 2006
- Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers.2005
- TelmisartanDrugs, 2001
- Pharmacokinetics of Orally and Intravenously Administered Telmisartan in Healthy Young and Elderly Volunteers and in Hypertensive PatientsJournal of International Medical Research, 2000
- The Acute Respiratory Distress SyndromeNew England Journal of Medicine, 2000